Intravitreal Triamcinolone Versus Bevacizumab for Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion.
10.3341/jkos.2010.51.8.1071
- Author:
Hosoong KIM
1
;
Sangjung MOON
;
Jaehoon KANG
;
Heesung YOON
Author Information
1. Sungmo Eye Hospital, Korea. heesyoon@dreamwiz.com
- Publication Type:Original Article
- Keywords:
Bevacizumab;
Branch retinal vein occlusion;
Macular edema;
Triamcinolone
- MeSH:
Antibodies, Monoclonal, Humanized;
Follow-Up Studies;
Humans;
Intravitreal Injections;
Macular Edema;
Retinal Vein;
Retinal Vein Occlusion;
Retinaldehyde;
Retrospective Studies;
Tomography, Optical Coherence;
Triamcinolone;
Triamcinolone Acetonide;
Visual Acuity;
Bevacizumab
- From:Journal of the Korean Ophthalmological Society
2010;51(8):1071-1076
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To compare clinical outcomes after intravitreal injection of triamcinolone acetonide or bevacizumab for the treatment of macular edema secondary to branch retinal vein occlusion. METHODS: Sixty-six patients received an intravitreal injection of either triamcinolone acetonide or bevacizumab. Patients were retrospectively reviewed. Thirty-three out of 66 patients were treated with an intravitreal injection of triamcinolone acetonide, while the other 33 patients received a bevacizumab injection. All patients underwent a visual acuity test, optical coherence tomography imaging and ophthalmoscopic examination throughout the follow-up. RESULTS: In the triamcinolone group, central macular thickness (CMT) decreased from 496.69 +/- 153.01 micrometer at baseline to 313.06 +/- 150.14 micrometer at the six-month follow-up visit, while in the bevacizumab group, CMT decreased from 441.30 +/- 185.79 micrometer to 295.67 +/- 188.80 micrometer (p<0.05). In the triamcinolone group, best-corrected visual acuity (BCVA) improved from logMAR 0.92 +/- 0.70 at baseline to logMAR 0.53 +/- 0.43 at the six-month follow-up visit, and in the bevacizumab group, BCVA improved from logMAR 0.74 +/- 0.47 to logMAR 0.34 +/- 0.33 (p<0.05). CONCLUSIONS: The therapeutic effects of intravitreal triamcinolone acetonide showed no significant differences compared with those of intravitreal bevacizumab with regard to anatomical and functional outcomes.
